Geode Capital Management, LLC Biocryst Pharmaceuticals Inc Transaction History

Geode Capital Management, LLC

$1.12 Trillion
Q2 2024

A detailed history of Geode Capital Management, LLC transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Geode Capital Management, LLC holds 4,710,277 shares of BCRX stock, worth $37.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

4,710,277

Previous 4,400,271 7.05%

Holding current value

$37.6 Million

Previous $22.4 Million 30.22%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	BUY	$4.13 - $6.79 $1.28 Million - $2.1 Million	310,006 Added 7.05%	4,710,277 $29.1 Million
Q1 2024 May 13, 2024	BUY	$4.89 - $7.65 $682,805 - $1.07 Million	139,633 Added 3.28%	4,400,271 $22.4 Million
Q4 2023 Feb 13, 2024	BUY	$4.98 - $6.77 $1.74 Million - $2.37 Million	349,561 Added 8.94%	4,260,638 $25.5 Million
Q3 2023 Nov 13, 2023	BUY	$6.71 - $7.92 $526,882 - $621,894	78,522 Added 2.05%	3,911,077 $27.7 Million
Q2 2023 Aug 11, 2023	BUY	$6.96 - $8.81 $1.25 Million - $1.58 Million	178,999 Added 4.9%	3,832,555 $27 Million
Q1 2023 May 15, 2023	BUY	$7.94 - $11.84 $1.48 Million - $2.21 Million	187,006 Added 5.39%	3,653,556 $30.5 Million
Q4 2022 Feb 13, 2023	BUY	$10.5 - $14.2 $1.06 Million - $1.43 Million	100,706 Added 2.99%	3,466,550 $39.8 Million
Q3 2022 Nov 14, 2022	BUY	$10.79 - $14.81 $902,982 - $1.24 Million	83,687 Added 2.55%	3,365,844 $42.4 Million
Q2 2022 Aug 12, 2022	BUY	$7.89 - $17.88 $1,412 - $3,200	179 Added 0.01%	3,282,157 $34.7 Million
Q1 2022 May 13, 2022	BUY	$11.56 - $19.76 $734,083 - $1.25 Million	63,502 Added 1.97%	3,281,978 $53.4 Million
Q4 2021 Feb 11, 2022	BUY	$11.18 - $15.46 $882,962 - $1.22 Million	78,977 Added 2.52%	3,218,476 $44.6 Million
Q3 2021 Nov 12, 2021	BUY	$14.21 - $17.65 $382,774 - $475,438	26,937 Added 0.87%	3,139,499 $45.1 Million
Q2 2021 Aug 13, 2021	BUY	$9.5 - $17.24 $1.16 Million - $2.1 Million	122,039 Added 4.08%	3,112,562 $49.2 Million
Q1 2021 May 12, 2021	BUY	$7.37 - $13.61 $2.46 Million - $4.55 Million	334,394 Added 12.59%	2,990,523 $30.4 Million
Q4 2020 Feb 12, 2021	BUY	$3.37 - $8.61 $715,845 - $1.83 Million	212,417 Added 8.69%	2,656,129 $19.8 Million
Q3 2020 Nov 13, 2020	BUY	$3.43 - $5.53 $799,049 - $1.29 Million	232,959 Added 10.54%	2,443,712 $8.39 Million
Q2 2020 Aug 13, 2020	BUY	$1.9 - $5.61 $13,442 - $39,690	7,075 Added 0.32%	2,210,753 $10.5 Million
Q1 2020 May 14, 2020	BUY	$1.6 - $4.11 $469,238 - $1.21 Million	293,274 Added 15.35%	2,203,678 $4.41 Million
Q4 2019 Feb 13, 2020	BUY	$1.59 - $3.45 $678,996 - $1.47 Million	427,042 Added 28.79%	1,910,404 $6.59 Million
Q3 2019 Nov 12, 2019	SELL	$2.5 - $3.73 $8,092 - $12,074	-3,237 Reduced 0.22%	1,483,362 $4.25 Million
Q2 2019 Aug 14, 2019	BUY	$2.91 - $9.15 $471,681 - $1.48 Million	162,090 Added 12.24%	1,486,599 $5.63 Million
Q1 2019 May 14, 2019	BUY	$7.38 - $9.72 $713,985 - $940,371	96,746 Added 7.88%	1,324,509 $10.8 Million
Q4 2018 Feb 13, 2019	BUY	$6.51 - $9.6 $708,190 - $1.04 Million	108,785 Added 9.72%	1,227,763 $9.91 Million
Q3 2018 Nov 13, 2018	BUY	$5.52 - $7.99 $637,460 - $922,701	115,482 Added 11.51%	1,118,978 $8.54 Million
Q2 2018 Aug 14, 2018	BUY	$4.6 - $6.52 $578,887 - $820,509	125,845 Added 14.34%	1,003,496 $5.75 Million
Q1 2018 May 15, 2018	BUY	$4.35 - $5.82 $253,326 - $338,933	58,236 Added 7.11%	877,651 $4.19 Million
Q4 2017 Feb 13, 2018	BUY	$4.16 - $5.33 $298,126 - $381,974	71,665 Added 9.58%	819,415 $4.02 Million
Q3 2017 Nov 14, 2017	BUY	$4.1 - $5.97 $381,980 - $556,201	93,166 Added 14.23%	747,750 $3.92 Million
Q2 2017 Aug 14, 2017	BUY	N/A	654,584	654,584 $3.64 Million

Others Institutions Holding BCRX

# of Institutions

258

Shares Held

173M

Call Options Held

397K

Put Options Held

444K

View Full List

About BIOCRYST PHARMACEUTICALS INC

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.48B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

More about BCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.

Account

Geode Capital Management, LLC Biocryst Pharmaceuticals Inc Transaction History